1, CD3-MUC1 new bispecific antibody development;
2, CD16-MUC1 new bispecific antibody development;
3, CD3-MUC1 new bispecific antibody development;
4, CD3-CD20 new bispecific antibody development;
5, CD3-HER2 new bispecific antibody development;
6, CD3-CD38 new bispecific antibody development;
7, CD3-BCMA new bispecific antibody development;
8, T cell efficient amplification technique optimization;
9, NK cell efficient amplification technology optimization;
10, Targeted activated CIK cells in the treatment of advanced liver cancer randomized, controlled clinical study; cooperation unit: People's Liberation Army 302 Hospital;
11, targeted MUC1 new bispecific antibody combined with autologous T cells in the treatment of lung cancer clinical research; cooperation unit: Shenzhen People's Hospital;
12, the new bispecific antibody combined with activated T cells in the treatment of children with refractory leukemia; cooperation unit: Sun Yat-sen Sun Yat-sen Memorial Hospital cooperation.